ArticleMolecular imaging and biology2022
Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study.
Article in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Performance of [European radiology · 2024Pooled it
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Radiopharmaceuticals in Renal Imaging: A Comprehensive Review of Current Applications and Future Prospects.ACS omega · 2026Review
- Integrated [European journal of nuclear medicine and molecular imaging · 2026Article
- FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.European journal of nuclear medicine and molecular imaging · 2025Article
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- The diagnostic value of [European radiology · 2024Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- [Respiratory research · 2023Article
- Head-to-head comparison ofCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Review
- Non-oncologic incidental uptake on FAPI PET/CT imaging.The British journal of radiology · 2023Review
- Performance and Prospects of [Cancers · 2022Review
- Comparison of physiological uptake of normal tissues in patients with cancer usingFrontiers in nuclear medicine · 2022Article
- Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to compare the primary staging of F-18 labeled fibroblast activation protein inhibitor ([ PROCEDURES: We prospectively analyzed the images of LAD patients who underwent [
resultsThirty-four LAD patients were evaluated. Patients showed high [
conclusions[
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.